Lessons from regulatory agilities during the COVID-19 pandemic: views from members of National Regulatory Authorities
This report aims to explore the perspective of members of NRAs on the use of regulatory agilities which emerged during the COVID-19 pandemic and describe lessons learnt from this experience.
Read more
The role of vaccines in tackling influenza
With new modelling from the Centers for Disease Control and Prevention (CDC) estimating up to 650,000 deaths annually associated with respiratory diseases from seasonal influenza, here I look at the important and on-going role vaccines play in tackling the disease and the innovations helping increase prevention. Influenza, commonly known as flu, is an acute respiratory...
Read moreThe largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all stakeholders
The AMR Industry Alliance has made major strides in 2018 taking action across four different areas to tackle the public health threat of AMR: research and science, access, appropriate use, and manufacturing and the environment. In 2018, it has published its first progress report that provides unique insights into the practical steps its members are...
Read moreComment on WHO announcement that COVID-19 no longer a Public Health Emergency of International Concern
IFPMA comment on WHO announcement that COVID-19 no longer constitutes a PHEIC.
Read moreTaking action on AMR: Largest life sciences sector coalition shows leadership in R&D, appropriate use and access to antibiotics and responsible manufacturing
Today the AMR Industry Alliance released its latest Progress Report, reflecting on collective achievements from the life sciences industry to minimize the spread of antimicrobial resistance (AMR).
Read moreMobilizing private sector contributions to resilient and equitable health systems – what will it take?
In this blog, originally published on UHC2030, UHC2030’s Private Sector Constituency shares some examples of how the private sector contributes to strengthening health systems for UHC and health security.
Read moreIFPMA COVID-19 Innovation Timeline
This timeline illustrates how the innovative pharmaceutical industry came together with the broader global health community to respond to the COVID-19 pandemic with unprecedented speed and scale, overcoming significant hurdles along the way.
Read more
COVID-19: An Unprecedented Mobilization of the Scientific Community
COVID-19: An Unprecedented Mobilization of the Scientific Community On Thursday, 26 February 2020, Thomas Cueni spoke to Suisse media (RTS La Matinale). He explains how the innovative biopharmaceutical member companies of IFPMA are already helping and are taking practical steps to engage. Those companies with potentially relevant knowhow have teams of scientists checking their libraries...
Read moreIFPMA Response to the Release of the ACT-A Evaluation Report
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) was a founding member of ACT-A when it was launched in April 2020. We welcomed the vision of the ACT-A to involve the private sector, including the innovative pharmaceutical industry, to join this unique global collaboration set up to accelerate development, production, and equitable access to...
Read moreIFPMA statement at the 74th session of the WHO Regional Committee for the Americas on the COVID-19 pandemic in the region of the Americas
28 September 2022, Washington, DC, USA — IFPMA welcomes the opportunity to share our from Covid-19 Lessons Learned, which highlights that swift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility must be preserved to ensure our collective ability to fight against unknown diseases. The most important lesson of the report is that...
Read more